Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
AssigneeThe Johns Hopkins University
InventorsBruce S. Bochner, Ronald L. Schnaar
Life of this patent
Estimating the term…
Abstract
The invention provides therapeutic methods and compositions for the prevention and treatment of Siglec-8 associated diseases and disorders such as asthma and allergic reactions. In particular, the invention provides methods and compositions for the prevention and treatment of diseases and disorders associated with Siglec-8 expressing cells in humans, as well as other animals, through the administration of one or more novel, carbohydrate-based compounds.
Claims16
The compound NeuAcα2-3(6-O-sulfo)Galβ1-4(Fucα1-3)GlcNAcβ-O—(CH2)3—NH—CO(CH2)5NH-M, where M is a hydrogen or amide linkage;
- or a pharmaceutically acceptable salt thereof.
A method for treating a subject suffering from or susceptible to a disease or disorder involving activation of Siglec-8 on Siglec-8 expressing cells comprising administering to the subject an effective amount of one or more compounds represented by the formula:
- in which
- A is a sialic acid residue or an analog thereof;
- B is a galactose residue or an analog thereof, and is substituted with an anionic moiety at the 6-position;
- C is an N-acetylglucosamine residue or an analog thereof;
- D is a fucose residue or an analog thereof;
- and
- R together with the O atom to which it is attached, is an aglycone;
- or a pharmaceutically acceptable salt thereof.
A compound represented by the formula:
- in which
- A is a sialic acid residue or an analog thereof;
- B is a galactose residue or an analog thereof, and is substituted with an anionic moiety at the 6-position;
- C is an N-acetylglucosamine residue or an analog thereof;
- D is a fucose residue or an analog thereof;
- and
- wherein R, together with the O atom to which it is attached is an aglycone represented by the structure —O—(CH2)3—NH—CO(CH2)5NH-M, where M is a hydrogen or an amide linkage;
- or a pharmaceutically acceptable salt thereof.
A compound represented by the formula:
- wherein R together with the O atom to which it is attached is an aglycone represented by the structure —O—(CH2)3—NH—CO(CH2)5NH-M, where M is a hydrogen or an amide linkage;
- and
- Y is independently for each occurrence an anionic group selected from the group consisting of carboxylate, sulfate, sulfonate, phosphate, phosphonate and hydroxamate;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.